Friday, March 29, 2019 -- Filgotinib, a JAK inhibitor that Gilead's bet heavily on, met the goals of two large Phase 3 trials. But its road through the FDA remains uncertain.
Tuesday, March 26, 2019 -- (MENAFN - PR Newswire) NORTH CHICAGO, Ill., March 26, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, today announced that the Japane...
Monday, March 25, 2019 -- Researchers at Tokai University report in the journal npj Regenerative Medicine a regenerative medicine approach for treating osteoarthritis of the knee.
Thursday, March 28, 2019 -- With this approval, certolizumab pegol becomes the first FDA-approved therapy for this type of axSpA, filling an unmet clinical need for treatment options, according to the release.